Literature DB >> 35358797

Dysregulation of miR-411 in cancer: Causative factor for pathogenesis, diagnosis and prognosis.

Mengsha Zou1, Jinze Shen2, Yuchen Wu3, Chenming Zhong4, Li Fang5, Feng Zhu6, Shiwei Duan7.   

Abstract

MiRNA accounts for 1-3% of genes but regulates more than 30% of gene expression in humans. This article analyzes the current deficiencies and challenges of miR-411 research and looks forward to the prospects of miR-411 in cancer. MiR-411 is a non-coding RNA located on chromosome 14. MiR-411 is abnormally expressed in a variety of cancers. The dysregulation of miR-411 can affect cancer cell proliferation, invasion, migration, apoptosis, colony formation, etc. miR-411 can be regulated by different lncRNAs and circRNAs. By targeting multiple genes, miR-411 participates in the activation of the MAPK signaling pathway, PI3K/AKT/mTOR signaling pathway, p53 signaling pathway, Ras signaling pathway, NF-κB signaling pathway, and Wnt/β-catenin signaling pathway. The expression of miR-411 is related to the diagnosis, prognosis, and sensitivity of drugs in cancer patients. In conclusion, this work outlines the molecular mechanisms and cellular functions of aberrant expression of miR-411 and its target genes in cancer to reveal its potential value in diagnosis, prognosis, and drug sensitivity.
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Diagnosis; MiR-411; Pathway; Prognosis; Target gene; Tumor

Mesh:

Substances:

Year:  2022        PMID: 35358797     DOI: 10.1016/j.biopha.2022.112896

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  1 in total

Review 1.  Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis.

Authors:  Jinze Shen; Chenhao Liang; Xinming Su; Qurui Wang; Yufei Ke; Jie Fang; Dayong Zhang; Shiwei Duan
Journal:  Biomark Res       Date:  2022-09-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.